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ABSTRACT 
 
Pain is the net effect of multidimensional mechanisms that engage most parts of the central 
nervous system (CNS) and the treatment of pain is one of the key challenges in clinical medicine 
(Le Bars et al., 2001; Miranda et al., 2008). Polypharmacy is seen as a barrier to analgesic 
treatment compliance, signifying the necessity for the development of fixed dose combinations 
(FDCs), which allow the number of tablets administered to be reduced, with no associated loss in 
efficacy or increase in the prevalence of side effects (Torres Morera, 2004). FDCs of analgesic 
drugs with differing mechanisms of nociceptive modulation offer benefits including synergistic 
analgesic effects, where the individual agents act in a greater than additive manner, and a 
reduced occurrence of side-effects (Raffa, 2001; Camu, 2002).  
 
This study aimed at producing a novel, rate-modulated, fixed-dose analgesic formulation for the 
treatment of mild to moderate pain. The fixed-dose combination (FDC) rationale of paracetamol 
(PC), tramadol hydrochloride (TM) and diclofenac potassium (DC) takes advantage of previously 
reported analgesic synergy of PC and TM as well as extending the analgesic paradigm with the 
addition of the anti-inflammatory component, DC. 
 
The study involved the development of a triple-layered tablet delivery system with the desired 
release characteristics of approximately 60% of the PC and TM being made available within 2 
hours to provide an initial pain relief effect and then sustained zero-order release of DC over a 
period of 24 hours to combat the on-going effects of any underlying inflammatory conditions. The 
triple-layered tablet delivery system would thus provide both rapid onset of pain relief as well as 
potentially address an underlying inflammatory cause. 
 
The design of a novel triple-layered tablet allowed for the desired release characteristics to be 
attained. During initial development work on the polymeric matrix it was discovered that only 
when combined with the optimized ratio of the release retarding polymer polyethylene oxide 
(PEO) in combination with electrolytic-crosslinking activity, provided by the biopolymer sodium 
alginate and zinc gluconate, could the 24 hour zero-order release of DC be attained. It was also 
necessary for this polymeric matrix to be bordered on both sides by the cellulosic polymers 
containing PC and TM. Thus the application of multi-layered tableting technology in the form of a 
triple-layered tablet were capable of attaining the rate-modulated release objectives set out in the 
study. The induced barriers provided by the three layers also served to physically separate TM 
and DC, reducing the likelihood of the bioavailability-diminishing interaction noted in United 
States Patent 6,558,701 and detected in the DSC analysis performed as part of this study. 
 
The designed system provided significant flexibility in modulation of release kinetics for drugs of 
varying solubility. The suitability of the designed triple-layered tablet delivery system was 
confirmed by a Design of Experiments (DoE) statistical evaluation, which revealed that 
Formulation F4 related closest to the desired more immediate release for PC and TM and the 
zero-order kinetics for DC. The results were confirmed by comparing Formulation F4 to typical 
release kinetic mechanisms described by Noyes-Whitney, Higuchi, Power Law, Pappas-Sahlin 
and Hopfenberg. Using f1 and f2 fit factors Formulation F4 compared favourably to each of the 
criteria defined for these kinetic models. 
 
The Ultra Performance Liquid Chromatographic (UPLC) assay method developed displayed 
superior resolution of the active pharmaceutical ingredient (API) combinations and the linearity 
plots produced indicated that the method was sufficiently sensitive to detect the concentrations of 
each API over the concentration ranges studied. The method was successfully validated and 
hence appropriate to simultaneously detect the three APIs as well as 4-aminophenol, the 
degradation product related to PC. 
 
Textural profile analysis in the form of swelling as well as matrix hardness analysis revealed that 
an increase in the penetration distance was associated with an increase in hydration time of the 
tablet and also an increase in gel layer thickness. The swelling complexities observed in the 
delivery system in terms of both the PEO, crosslinking sodium alginate and both cellulose 
polymers as well as the actuality of the three layers of the tablet swelling simultaneously suggests 
further intricacies involved in the release kinetics of the three drugs from this tablet configuration. 
 
Modified release dosage forms, such as the one developed in this study, have gained widespread 
importance in recent years and offer many advantages including flexible release kinetics and 
improved therapy and patient compliance.  
 
Key Words: analgesic, pain, paracetamol, tramadol, diclofenac, polymer, PEO, layered tablet, 
zero-order release, first-order release. 
 
